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Background: The Medtronic implantable cardioverter deﬁbrillator (ICD) and cardiac resynchronization
therapy with deﬁbrillator (CRT-D) device is equipped with the OptiVol ﬂuid status monitoring system,
which continuously measures intrathoracic impedance and provides an early warning of thoracic ﬂuid
retention, which is indicative of decompensated heart failure (HF). The accuracy of the telediagnosis of
HF with this system still remains to be elucidated.
Methods: We studied 82 chronic HF patients implanted with a Medtronic ICD/CRT-D (mean age 66712
years, 62 men, ICD in 44 and CRT-D in 38, left ventricular ejection fraction 37714%). During follow-up,
we analyzed OptiVol alerts, which were sent by monthly scheduled transmission and by unscheduled
CareAlerts transmission for threshold-crossing events. The elevation patterns of OptiVol Fluid Index
(OVFI), including the duration of threshold crossing, time interval from threshold crossing to peak OVFI,
and peak OVFI, were compared between true decompensated HF and false-positive events.
Results: During a mean period of 8617239 days, 612 OptiVol alerts were transmitted from 70 of the 82
patients (85.4%). These 612 alerts were derived from 298 episodes that potentially represented decompensated
HF (2.1 alerts per episode). Of these 298 possible HF events, 119 (40%) were judged as true decompensated HF
based on clinical ﬁndings, while the other 179 events (60%) were false positives, including unexpected OVFI
elevation (n¼83), paroxysmal atrial ﬁbrillation (n¼37), excessive exercise (n¼18), non-sustained ventricular
tachycardia (n¼10), and other causes. The analysis of the OVFI elevation pattern revealed that both the
duration of threshold crossing and the peak OVFI value were signiﬁcantly related to decompensated HF. The
cutoff value for the duration of threshold crossing of OVFI for the diagnosis of HF was 21 days, showing 87%
sensitivity and 85% speciﬁcity. The cutoff value of OVFI peak was 136.0 Ω, showing 90% sensitivity and 92%
speciﬁcity.
Conclusions: Not every OptiVol alert is indicative of decompensated HF. A threshold-crossing OVFI for 421
days and an OVFI peak4136Ω are both strongly indicative of decompensated HF, and may be useful in the
telediagnosis of HF.
& 2013 Japanese Heart Rhythm Society. Published by Elsevier B.V. All rights reserved.1. Introduction
The early prediction and diagnosis of heart failure (HF) are
important when managing patients with chronic HF. In the Tele-HF
study [1], the incidence of decompensated HF events over a 180-day
period was compared between patient groups with and without home
monitoring of HF symptoms and body weight with the use of a
telephone circuit. The study noted no differences in the rates of
readmission and all-cause mortality between the 2 groups, revealingt Rhythm Society. Published by Els
, Respiratory Medicine and
edicine 5 Zaifu-cho, Hirosaki,
5 9190.
kumura).the limitation of monitoring only HF symptoms and body weight.
Recently, remote monitoring with the use of cardiovascular implan-
table electric devices has been developed, and the feasibility of the
early diagnosis of HF has been investigated. Intrathoracic impedance
was shown to be inversely correlated with the total body ﬂuid volume
and pulmonary wedge pressure [2]; thus, early diagnosis of HF by
continuous impedance monitoring was feasible. The Medtronic
remote monitoring system, CareLink Network, allows not only early
detection of a malfunction of the implanted device and arrhythmic
events, but also continuous intrathoracic impedance monitoring via
OptiVols Fluid Status monitoring alerts™.
The OptiVol Fluid Index (OVFI), which is derived from changes
in intrathoracic impedance, can effectively assess HF by analyzing
the changes in the intrathoracic impedance detected by theevier B.V. All rights reserved.
Table 1
Baseline characteristics of the subjects.
Variable Patients (n¼82)
Age (year) 66712
Male gender 62 (75.6%)
LVEF (%) 37714
ICD/CRT-D 44/38
Chronic atrial ﬁbrillation 11 (13.4%)
Coronary artery disease 31 (37.8%)
Medication
Amiodarone 34 (41.4%)
Beta-blocker 73 (89%)
ACE/ARB 61 (74.4%)
Diuretics 62 (75.6%)
ACE-I: angiotensin-converting enzyme inhibitor,
ARB: angiotensin II receptor blocker, LVEF: left
ventricular ejection fraction
S. Sasaki et al. / Journal of Arrhythmia 29 (2013) 347–352348original OptiVol algorithm. Small et al. previously determined that
a frequent and extended threshold crossing period of OVFI was
correlated with actual events of decompensated HF in patients
implanted with a cardiac resynchronization therapy with deﬁbril-
lator (CRT-D) device, and suggested that early prediction of
decompensated HF and reduction of hospitalization for HF were
possible by monitoring changes in OVFI [3]. Several recent reports,
however, have raised concerns about the considerably high false
positive rate of decompensated HF events using the original
OptiVol algorithm. Ypenburg et al. reported that HF symptoms
were actually observed in only 33% of patients in whom OptiVol
alerts occurred with the OVFI threshold set at 60 Ω [4]. In the
Medtronic Impedance Diagnostics in Heart Failure Patients Trial
(MIDHEFT), the sensitivity of OVFI in the diagnosis of HF was 77%,
and the frequency of non-HF events with OVFI elevation crossing
the threshold (false-positive rate) was 1.5 per year per patient [5].
The corresponding results from the Fluid Accumulation Status
Trial (FAST) were similar, at 76% and 1.9% per year per patient,
respectively [6].
In this study, we investigated the feasibility of using OVFI
monitoring based on the original OptiVol algorithm in the early
telediagnosis of decompensated HF in patients with reduced left
ventricular function who were implanted with the Medtronic
implantable cardioverter deﬁbrillator (ICD) or CRT-D device. We
focused on the elevation patterns of OVFI, such as the duration of
threshold crossing, the time interval from threshold crossing to
peak OVFI, and peak OVFI, and compared the parameters between
true decompensated HF and false-positive events.2. Methods
2.1. Study patients
This study included 82 patients with chronic HF due to organic
heart diseases, who were treated with Medtronic ICD or CRT-D
implantation for primary (n¼32) or secondary prevention (n¼50) of
sudden cardiac death between September 2009 and December 2012.
There were 62 men and 20 women, and their mean age was 66712
years. An ICD was implanted in 44 and a CRT-D device in the other 38.
The mean left ventricular ejection fraction (LVEF) measured by
transthoracic echocardiography or left ventriculography was 377
14%. The underlying heart diseases included coronary artery disease
(CAD) in 31 patients (38%), dilated cardiomyopathy (DCM) in 22 (27%),
hypertrophic cardiomyopathy including diastolic phase hypertrophic
cardiomyopathy in 16 (20%), arrhythmogenic right ventricular cardi-
omyopathy (ARVC) in 3, cardiac sarcoidosis in 4, and congenital heart
disease and vascular disease in the remaining 6. The baseline clinical
characteristics of these patients are shown in Table 1.
2.2. Device and CareLink Network setting
The device implanted was a Medtronic ICD, including the
Marquis DR/7274, 7230Cx, Maximo DR/7278, Maximo VR/
7232Cx, Virtuoso DR/D164AWG, Virtuoso DR/D164VWC, Secura
DR/D234DRG, and Secura VR/D234VRC, or a Medtronic CRT-D
including the Concerto/C154DWK and Consulta CRT-D/D234CRK,
all of which were equipped with the CareLink Network system.
The data transmission interval through the system was set at once
per month. Via the CareLink system, monthly scheduled data
transmission and unscheduled transmission of CareAlerts for
threshold-crossing events were executed, and all events, includ-
ing cardiac episodes and OptiVol alerts, were recorded. As the
CareLink system continues sending Optivol alerts until impedance
monitoring is reset, several Optivol alerts could be derived from a
single HF event.2.3. OVFI analysis method and deﬁnition of heart failure events
The following parameters were measured for every OptiVol alert
event detected by the original OptiVol algorithm, OptiVol version 1.0,
and were transmitted through CareLink: (1) the time taken to reach
the peak value once OVFI elevation had crossed the threshold; (2) the
peak OVFI value; and (3) the duration of OVFI elevation above the
threshold (Fig. 1). The OVFI threshold was set at 60Ω. In the analysis of
the peak OVFI value, any value exceeding 200 Ω, which is the upper
limit for the OVFI elevation crossing value on CareLink, was analyzed
as 200 Ω. OptiVol alert events detected within 40 days after device
implantation were excluded as post-implantation reductions in impe-
dance, presumably due to surgery-related device pocket inﬂammation.
Decompensated HF was deﬁned as a condition in which 2 of the
following 3 signs became positive within 30 days after the ﬁrst time the
OVFI elevation crossed the threshold: the exacerbation of HF symptoms
(i.e., breathlessness, orthopnea, paroxysmal nocturnal dyspnea, reduced
exercise tolerance, fatigue, and ankle swelling), the appearance of
pulmonary congestion on the chest X-ray ﬁlm, and elevation of the
plasma brain natriuretic peptide (BNP) level by 4100 pg/mL compared
with the value measured previously. When the OptiVol alerts were
received, intervention was limited to making phone calls to patients to
call their attention to the incident, and/or adjusting oral drug treatment
as part of outpatient care. If a patient was hospitalized and received
medical intervention such as intravenous administration of a catecho-
lamine, diuretic, or vasodilator, that patient's data were excluded from
the analysis.
2.4. Statistical analysis
Values are presented as mean7standard deviation. Between-
group comparisons were made using Student's t-test. Multivariate
analysis was performed to assess the accuracy of the OptiVol-
based diagnosis of heart failure and the elevation pattern of OVFI.
A value of Po0.05 was regarded as signiﬁcant. All analyses were
carried out using a JMP 9 Pro (SAS Institute Inc., Cary, North
Carolina, USA).3. Results
3.1. Event transmission through the CareLink system
During the observation period (mean 8617239 days), a total of
1468 event transmissions were conﬁrmed in 81 of the 82 patients
(98.7%). The events included 612 OptiVol alerts (41.7%), 308 episodes
of paroxysmal atrial ﬁbrillation or atrial tachycardia (AF/AT) (21.0%),
246 episodes of non-sustained ventricular tachycardia (NSVT)
Time interval from threshold 
crossiing to peak OVFI
Peak value 
of OVFI
threshold crossing
Duration of threshold 
crossing
threshold 
Fig. 1. OVFI elevation pattern and its analysis. The time to reach the peak after OVFI crosses the threshold (60 Ω) (threshold crossing), the peak value, and the duration of
threshold crossing were measured in OptiVol alert events.
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dia (VT)/ventricular ﬁbrillation (VF) (5%), 32 episodes of inappropri-
ate therapy (2.2%), 33 episodes of VT detection without therapy
(2.2%), 29 episodes of supraventricular tachycardia (2.0%), 130 epi-
sodes of reduced pacing rate in the CRT device (8.9%), and 17 other
events, such as device battery drain (Fig. 2). OptiVol alerts were sent
from 70 of the 82 patients (85.4%) and were derived from 298
episodes that potentially represented decompensated HF (2.1 alerts
per episode).Fig. 2. Events transmitted through the CareLink system.3.2. True and false decompensated HF events by OptiVol alerts
Of the 298 OptiVol alert episodes, 119 episodes (40%) were
judged as decompensated HF and 179 (60%) as false positives. The
diagnosis of decompensated HF was based on exacerbation of HF
symptoms in 117 cases (98.3%), on pulmonary congestion in 88
(73.9%), and on a signiﬁcant elevation of BNP level in 117 (98.3%).
Thirty-ﬁve (29.4%) episodes satisﬁed 2 of these criteria and 84
had all. The most frequent reason for false-positive events was
OVFI elevation of unknown cause (83 episodes, 47%), followed by
37 episodes (21%) of paroxysmal AF/AT, 18 (10%) of excessive
exercise and overwork, 10 (6%) of NSVT, 9 (5%) of treatment for
other diseases, 7 (4%) of excessive salt intake, 7 (4%) of body
weight gain, 5 (3%) of treatment for VT/VF, and 3 of device pocket
swelling.3.3. Analysis of the OVFI elevation pattern
The OVFI elevation patterns were compared between the patient
groups with true decompensated HF and false-positive events. As
shown in Fig. 3, the time interval to reach the peak after crossing the
threshold was 20.878.8 days in the decompensated HF group and
10.278.4 days in the false-positive group (Po0.0001). The duration
of threshold crossing was 45.8736.1 in the decompensated and
14.6718.3 days in the false-positive group (Po0.0001). The peak
Fig. 3. Comparison of OVFI elevation patterns between decompensated heart failure (HF+) and false-positive events (HF).
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in the false-positive group (Po0.0001). Representative examples of
the OVFI elevation pattern in patients with decompensated HF and
false-positive events are shown in Fig. 4.
Among these OVFI elevation patterns, multivariate analysis
revealed that the duration of OVFI elevation crossing the threshold
and peak OVFI value were signiﬁcant predictors of decompensated
HF (Table 2). The cutoff value of the duration of OVFI elevation
calculated from the receiver operating characteristic curve for the
accurate diagnosis of decompensated HF was 21 days, with an area
under the curve (AUC) of 0.907. Its sensitivity and speciﬁcity were
86.6% and 84.9%, respectively. The cutoff value of peak OVFI was
136.0 Ω (AUC 0.948), and its sensitivity and speciﬁcity were 89.9%
and 91.6%, respectively (Fig. 5).4. Discussion
In the present study, we collected OptiVol alerts from patients
who had a Medtronic ICD/CRT-D implanted and compared the
OVFI elevation patterns—the time to peak after crossing the
threshold, the duration of threshold crossing, and the peak OVFI
value—between true decompensated HF and false-positive
events. The results suggested that these OVFI indexes would
enhance the diagnostic accuracy of OptiVol ﬂuid status monitor-
ing, while reducing the unexplained threshold crossings that lead
to false-positive alerts. In particular, when OVFI has increased
slowly and exceeds the threshold for 421 days, or has reached
and remained at 4136 Ω, it is strongly predictive of
decompensated HF.
4.1. Limited accuracy of original OptiVol algorithm
Several studies previously reported that changes in intrathoracic
impedance are signiﬁcantly correlated with those in total body ﬂuid
volume and pulmonary arterial wedge pressure [5]. By continuously
monitoring intrathoracic impedance via the Medtronic CareLink
system, OptiVol measures daily impedance. The reference impedance
is calculated from the mean daily impedance over 4 days, starting 40
days after implantation of the device. OVFI is an index that iscalculated by continuously totaling the differences between the
reference and daily impedances, so that changes in body ﬂuid
volume can be clearly and visually observed in comparison with
those in daily impedance. In the original OptiVol algorithm, since the
difference between the reference and daily impedances is updated
continuously, OVFI elevation continues until the difference between
the reference and daily impedances is reset, even after daily
impedance elevation has started. Therefore, small changes in daily
impedance within a short time are not readily reﬂected, and OVFI
elevation with an unknown cause, i.e., a false-positive event, is likely
to occur. We performed this study in patients who had chronic HF
with a mean LVEF of 37%, but decompensated HF was noted in only
39.9% of the patients in whom an OptiVol alert occurred. In fact, OVFI
elevation was induced by diverse causes—such as atrial ﬁbrillation,
ventricular arrhythmias, deﬁbrillator therapy, increases in the activ-
ities of daily living and body weight of the patients, and pulmonary
diseases—suggesting that detection accuracy with the original Opti-
Vol algorithm alone is limited.
4.2. Usefulness of analysis of OVFI elevation pattern
Recent studies assessed the sensitivity of the original
OptiVol algorithm in predicting decompensated HF events
and have reported results in the range of 60–80%. In the FAST
study [6], a retrospective study of 156 HF patients with an ICD
or CRT-D, it was demonstrated that impedance monitoring
using OptiVol was more sensitive than conventional weight
monitoring in predicting decompensated HF (76.4% vs. 22.5%).
However, the SENSE-HF trial [7], a prospective multicenter
double-blind study, showed that the original OptiVol algorithm
had low sensitivity (42%) and a low positive predictive value
(38%) for decompensated HF. Thus, an improvement in the
diagnostic accuracy of OptiVol is needed. In order to enhance
the accuracy of the diagnosis of HF using the original OptiVol
algorithm, the OVFI elevation pattern, including the time to
reach peak after crossing the threshold, the duration of thresh-
old crossing, and the peak OVFI value, were analyzed, and their
clinical signiﬁcances were validated. For this purpose, we
compared each parameter between the patient groups with
decompensated HF and false-positive events. We found that,
Fig. 4. Representative examples of the OVFI elevation pattern in decompensated and false-positive events.
Table 2
Univariate and multivariate analyses of the accuracy of the diagnosis of heart failure by OVFI elevation pattern.
OVFI parameters Univariate analysis Multivariate analysis
OR 95% CI P-value OR 95% CI P-value
Time to peak 1.15 1.11–1.19 o0.0001
Duration of threshold crossing 1.09 1.07–1.12 o0.0001 0.98 0.97–0.99 0.0411
Value of peak OVFI 1.06 1.05–1.07 o0.0001 1.05 1.03–1.06 o0.0001
S. Sasaki et al. / Journal of Arrhythmia 29 (2013) 347–352 351when OVFI increased slowly and crossed the threshold for 421
days, or reached 4136 Ω, the episode was strongly associated
with decompensated HF. Thus, observation of the OVFI eleva-
tion pattern may improve the accuracy of the diagnosis of HF
when employing OptiVol.4.3. Limitation of early prediction of heart failure using OptiVol
The present analysis of the OVFI elevation pattern seems to be
useful in differentiating decompensated HF from false-positive
events. It may be pointed out that decompensated HF was deﬁned
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Fig. 5. ROC curves of the accuracy of the diagnosis of heart failure in relation to the duration of threshold crossing and OVFI peak. See text for discussion.
S. Sasaki et al. / Journal of Arrhythmia 29 (2013) 347–352352as the state in which a sign of congestion had already become
clear. This may be insufﬁcient for early prediction before the
development of HF. The OptiVol algorithm installed in the current
Medtronic ICD and CRT-D has been revised in order to reduce the
false-positive rate. The assessment of the OVFI elevation pattern
may be altered. The PARTNER-HF study [8] showed the usefulness
of early prediction and diagnosis of HF based on a marked increase
in OptiVol (4100 Ω) installed in the device or based on the
integrated diagnostic function of OptiVol and other diagnostic
parameters installed in Cardiac Compass. It remains to be inves-
tigated how to integrate OptiVol and the clinical information
obtained by the device, stratify the risks of HF, and establish an
early diagnostic method.5. Conclusions
OptiVol alert events based on the original OptiVol algorithm
included many false-positive episodes other than decompensated
HF, but it was possible to improve the diagnostic accuracy by
analyzing the OVFI elevation pattern. Speciﬁcally, when OptiVol
increases slowly and exceeds the threshold for 421 days, or
reaches 4136 Ω and persists, it is strongly associated with chronic
decompensated HF.Conﬂict of interest
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